AU2023400A - Compositions and methods for inhibiting angiogenesis using trna and fragments thereof - Google Patents

Compositions and methods for inhibiting angiogenesis using trna and fragments thereof

Info

Publication number
AU2023400A
AU2023400A AU20234/00A AU2023400A AU2023400A AU 2023400 A AU2023400 A AU 2023400A AU 20234/00 A AU20234/00 A AU 20234/00A AU 2023400 A AU2023400 A AU 2023400A AU 2023400 A AU2023400 A AU 2023400A
Authority
AU
Australia
Prior art keywords
trna
fragments
compositions
methods
inhibiting angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20234/00A
Inventor
Krzystof Bojanowski
M. Judah Folkman
Yuen Shing
Hui Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of AU2023400A publication Critical patent/AU2023400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU20234/00A 1998-11-12 1999-11-12 Compositions and methods for inhibiting angiogenesis using trna and fragments thereof Abandoned AU2023400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10803698P 1998-11-12 1998-11-12
US60108036 1998-11-12
PCT/US1999/026696 WO2000027340A2 (en) 1998-11-12 1999-11-12 USE OF t-RNA AND FRAGMENTS FOR INHIBITING ANGIOGENESIS AND COMPOSITIONS THEREOF

Publications (1)

Publication Number Publication Date
AU2023400A true AU2023400A (en) 2000-05-29

Family

ID=22319903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20234/00A Abandoned AU2023400A (en) 1998-11-12 1999-11-12 Compositions and methods for inhibiting angiogenesis using trna and fragments thereof

Country Status (2)

Country Link
AU (1) AU2023400A (en)
WO (1) WO2000027340A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002228749B2 (en) 2000-10-18 2008-04-24 Pharmasset Inc Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
PL2578685T3 (en) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
JP2014511687A (en) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド Engineered nucleic acid delivery and formulation
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (en) 2011-10-03 2022-06-28 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HRP20220717T1 (en) 2011-12-16 2022-07-22 Modernatx, Inc. Modified mrna compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243947A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
ES2921623T3 (en) 2012-11-26 2022-08-30 Modernatx Inc terminally modified RNA
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2940192C (en) 2014-02-04 2022-09-27 Thomas Jefferson University Specific expression of half-trna in cancers
WO2018119421A1 (en) * 2016-12-22 2018-06-28 Thomas Jefferson University Compositions and methods of using rna fragments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2824411A1 (en) * 1978-06-03 1979-12-13 Boehringer Sohn Ingelheim ANTIVIRAL T-RNA PREPARATIONS

Also Published As

Publication number Publication date
WO2000027340A9 (en) 2000-11-30
WO2000027340A2 (en) 2000-05-18
WO2000027340A3 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
AU2023400A (en) Compositions and methods for inhibiting angiogenesis using trna and fragments thereof
AUPQ419099A0 (en) Novel compositions and methods
AU2002246666A1 (en) Anti-icing composition
AU2001261566A1 (en) Well service composition and method
AU3616999A (en) Radiation-curable compositions
AU3085599A (en) Bone cement compositions
AU1740900A (en) Method of inhibiting angiogenesis
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
EP1015014A4 (en) Methods and compositions for inhibiting angiogenesis
AU2349399A (en) R-lansoprazole compositions and methods
AU5565099A (en) Pharmaceutical compositions and methods for use
AU2243797A (en) Methods and compositions for inhibiting hexokinase
AU3869200A (en) Method and composition for masking mineral taste
AU5638800A (en) High potassium polyphosphate and method for its preparation
AU2001251582A1 (en) Method and compositions for ordering restriction fragments
AU2640599A (en) An orally disintegrating composition and its manufacturing method
AU2970299A (en) Compositions and methods for polynucleotide delivery
AU4917499A (en) Refractory compositions
AU4440199A (en) Methods and compositions for inhibition of angiogenesis
AUPP332898A0 (en) Pharmaceutical composition
AU5571799A (en) Angiogenesis inhibitors and uses thereof
AU4198899A (en) Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
AU1156301A (en) Composition and process for oil extraction
HUP0101326A3 (en) Paroxetine compositions and process for their preparation
AU6217199A (en) Compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase